Skip to main content

Advertisement

Table 1 Breast cancer patient characteristics (categorial variables)

From: Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

Parameters All BC patients analyzed in this study HER2-positive patients TNBC patients All BC patients in GeparSixto trial p value*
Total 435 (100.0%) 211 (100.0%) 244 (100.0%) 588 (100.0%)
Subtype HER2-positive patients 211 (48.5%) Subgroups of all BC patients analyzed in this study 273 (46.4%) 0.0909
TNBC patients 224 (51.5%) 315 (53.6%)
Age < 50 249 (57.2%) 120 (56.9%) 129 (57.6%) 341 (58.0%) 0.5684
≥ 50 186 (42.8%) 91 (43.1%) 95 (42.4%) 247 (42.0%)
Lymph node metastasis N0 240 (56.1%) 106 (50.7%) 134 (61.2%) 338 (58.7%) 0.0333
N+ 188 (43.9%) 103 (49.3%) 85 (38.8%) 238 (41.3%)
Missing 7 2 5 12
Tumor size T1–2 365 (84.3%) 167 (79.9%) 198 (88.4%) 499 (85.2%) 0.3570
T3–4 68 (15.7%) 42 (20.1%) 26 (11.6%) 87 (14.8%)
Missing 2 2 0 2
Grading G1–2 151 (34.7%) 93 (44.1%) 58 (25.9%) 207 (35.2%) 0.6944
G3 284 (65.3%) 118 (55.9%) 166 (74.1%) 381 (64.8%)
Lymphocyte predominant breast cancer pos. 108 (25.1%) 44 (21.4%) 64 (28.6%) 142 (24.4%) 0.5825
neg. 322 (74.9%) 162 (78.6%) 160 (71.4%) 439 (75.6%)
Missing 5 5 0 7
Therapy arm PM 222 (51.0%) 109 (51.7%) 113 (50.4%) 293 (49.8%) 0.3478
PMCb 213 (49.0%) 102 (48.3%) 111 (49.6%) 295 (50.2%)
Pathological complete response (pCR) Yes 223 (51.3%) 113 (53.6%) 110 (49.1%) 296 (50.3%) 0.4540
No 212 (48.7%) 98 (46.4%) 114 (50.9%) 292 (49.7%)
  1. PM non-carboplatin treatment arm, PMCb carboplatin treatment arm
  2. *Characteristics of patients were compared between patients with analyzed samples and all patients of GeparSixto study (modified intend-to-treat population) using Fisher’s exact tests